Johnson & Johnson

Johnson & Johnson said it would reduce its global work force by up to 4 percent, or up to 4,820 jobs, to cut costs due to a slump in sales of its heart stents and its No. 2 drug, plus coming patent expirations for key drugs. The health care giant, which employees about 120,500 people in 57 countries, said the restructering, its largest ever,would bring pretax charges of $550 million to $750 million later this year, as well as other, unspecified steps besides job cuts.